Versor Investments LP Raises Holdings in Certara, Inc. $CERT

Versor Investments LP boosted its position in Certara, Inc. (NASDAQ:CERT) by 104.0% in the 2nd quarter, Holdings Channel reports. The fund owned 89,346 shares of the company’s stock after purchasing an additional 45,546 shares during the period. Versor Investments LP’s holdings in Certara were worth $1,045,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. ANTIPODES PARTNERS Ltd grew its stake in Certara by 22.5% in the 2nd quarter. ANTIPODES PARTNERS Ltd now owns 6,665 shares of the company’s stock worth $78,000 after acquiring an additional 1,223 shares during the period. Pier Capital LLC purchased a new stake in Certara in the 2nd quarter worth approximately $7,809,000. Geneva Capital Management LLC grew its stake in Certara by 7.8% in the 2nd quarter. Geneva Capital Management LLC now owns 6,114,895 shares of the company’s stock worth $71,544,000 after acquiring an additional 443,206 shares during the period. Quaker Wealth Management LLC grew its stake in Certara by 200.0% in the 2nd quarter. Quaker Wealth Management LLC now owns 12,535 shares of the company’s stock worth $147,000 after acquiring an additional 25,070 shares during the period. Finally, Mendel Money Management grew its stake in Certara by 24.9% in the 2nd quarter. Mendel Money Management now owns 134,305 shares of the company’s stock worth $1,571,000 after acquiring an additional 26,740 shares during the period. 73.96% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Certara

In other news, insider Leif E. Pedersen sold 51,224 shares of the firm’s stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $10.92, for a total value of $559,366.08. Following the transaction, the insider owned 73,979 shares of the company’s stock, valued at approximately $807,850.68. This trade represents a 40.91% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 2.33% of the company’s stock.

Certara Stock Performance

Shares of CERT stock opened at $11.63 on Monday. The company’s fifty day simple moving average is $11.77 and its 200-day simple moving average is $11.59. Certara, Inc. has a 52 week low of $8.64 and a 52 week high of $15.69. The company has a current ratio of 2.16, a quick ratio of 2.16 and a debt-to-equity ratio of 0.27. The company has a market cap of $1.87 billion, a PE ratio of 232.65 and a beta of 1.44.

Certara (NASDAQ:CERT) last issued its earnings results on Wednesday, August 6th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Certara had a net margin of 1.97% and a return on equity of 5.11%. The business had revenue of $104.57 million during the quarter, compared to analysts’ expectations of $104.14 million. During the same period in the prior year, the business posted $0.07 EPS. The business’s revenue was up 12.1% on a year-over-year basis. As a group, equities research analysts anticipate that Certara, Inc. will post 0.28 EPS for the current year.

Analyst Ratings Changes

Several research firms have commented on CERT. Craig Hallum began coverage on shares of Certara in a research note on Monday, September 29th. They issued a “buy” rating and a $16.00 target price for the company. KeyCorp lifted their target price on shares of Certara from $15.00 to $16.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 8th. UBS Group lowered their target price on shares of Certara from $17.50 to $15.00 and set a “buy” rating for the company in a research note on Thursday, August 7th. Weiss Ratings reiterated a “sell (d)” rating on shares of Certara in a report on Wednesday, October 8th. Finally, Barclays lifted their price target on shares of Certara from $14.00 to $16.00 and gave the company an “overweight” rating in a report on Thursday, October 2nd. Six equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $15.63.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.